摘要
目的探讨糖皮质激素联合环磷酰胺治疗重症肌无力的临床疗效及安全性。方法选取本院2015年1月~2016年7月收治的98例重症肌无力患者为研究对象,将其随机分成两组,分别为对照组和观察组,每组49例。两组均予以溴吡斯的明口服,对照组另单予糖皮质激素治疗,观察组在对照组基础上加用环磷酰胺治疗。记录比较两组临床效果及不良反应发生情况。结果治疗后,观察组总有效率明显高于对照组(P<0.05)。观察组住院时间、症状改善时间较对照组均显著缩短(P<0.01)。两组治疗期间均未发生严重不良反应。结论糖皮质激素联合环磷酰胺治疗重症肌无力能有效改善患者症状,临床效果明显,安全有效,值得临床应用。
Objective To investigate the clinical efficacy and safety of applying glucocorticoid combined with cyclophosphamide in treating myasthenia gravis. Methods 98 cases of patients with myasthenia gravis admitted in our hospital from January 2015 to July 2016 were selected as the study subjects, who were randomly divided into the control group and the obversation group, 49 cases in each group. Both groups were treated with oral pyridostigmine bromide. The control group was given glucocorticoid on the basis of pyridostigmine bromide, while the observation group was treated glucocorticoid combined with cyclophosphamide. The clinical efficacy and adverse reactions were recorded and compared between the two groups. Results The overall effective rate of the observation group after treatment was higher than that of the control group（P〈 0.05）. The time taken for hospital stay and improvement of symptoms in the observation group were much shorter than those in the control group（P 〈 0.01）. No severe adverse reactions were seen in the two groups during treatment. Conclusion The application of glucocorticoid combined with cyclophosphamide in treating myasthenia gravis proves to be safe and effective in improving the symptoms in patients, which is worth further clinical promotion.
作者
赵辉
ZHAO Hui(Department of Neurology,the First Afliated Hospital,and College of Clinical Medicine of Henan University of Science and Technology,Luoyang,Henan,471003,China)
出处
《临床研究》
2018年第6期98-99,共2页
Clinical Research
关键词
糖皮质激素
环磷酰胺
重症肌无力
glucocorticoid
cyclophosphamide
myasthenia gravis
